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A rapid and sensitive reversed phase high performance liquid chromatographic method has been 
developed for quantitative analysis of sparfloxacin in pharmaceutical preparations. The method was 
validated according to FDA, ICH and USP guidelines with respect to accuracy, precision, specificity 
and linearity. The method was developed using the mobile phase comprising 1% aqueous solution of 
acetic acid and acetonitrile in the ratio of 71: 29% (v/v) at a flow rate of 0.7 mL/min over C-8 bonded 
silica column at ambient temperature. The recovery was found to be more than 97% for each spiked 
samples of sparfloxacin demonstrative of accuracy of the protocol. Intraday and interday precision 
of the new method were less than the maximum allowable limit (RSD% 2.0) according to FDA. The 
method showed linear response with correlation coefficient value of 0.998.  Therefore, the method 
was found to be accurate, reproducible, sensitive and less time consuming, and can be successfully 
applied for the assay of sparfloxacin formulations. .
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RESUMEN
Un método rápido y sensible de cromatografía líquida en fase reversa de alta resolución ha sido 
desarrollado para el análisis cuantitativo de sparfloxacino en preparaciones farmacéuticas. El método 
fue validado de acuerdo a las normas de precisión, especificidad y linealidad aportadas por la FDA, 
ICH y USP. El método fue desarrollado utilizando la fase móvil compuesta por solución acuosa de 
ácido acético al 1% y acetonitrilo en la proporción 71:29% (v/v) bajo una velocidad de flujo de 0.7 
ml/min sobre una columna de sílice c-8 a temperatura ambiente. La recuperación fue de más del 
97% para cada muestra adicionada de sparfloxacino lo que demuestra la precisión del protocolo. La 
precisión intradía e interdía fue inferior al límite máximo permitido (RSD≤ 2.0), de acuerdo a la FDA. 
El método mostró una respuesta linear con un coeficiente de correlación del 0.998. Por lo tanto, el 
método fue preciso, reproducible, sensible y rápido, por lo que puede ser utilizado para el análisis 
de formulaciones de sparfloxacino.
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Sparfloxacin, a fluoroquinolone antibiotic, has been 
reported to be more active than other fluoroquinolones 
against some Gram-positive organisms such as Streptococcus 
pneumoniae, Staphylococcus aureus, Mycobacterium and 
Chlamydia species. Sparfloxacin is a potential antibiotic 
for use in the treatment of upper and lower respiratory 
tract infections including sinusitis, acute exacerbation 
of chronic bronchitis, community and hospital acquired 
pneumonia; urinary tract infections such as gonococcal and 
non-gonococcal urethritis, chancroid and other sexually 
transmitted diseases; skin and soft tissue infections, and 
prophylactic use in different urological and ophthalmic 
surgical procedures1-4.
Like other drugs sparfloxacin also requires some absolute 
quality parameters like quality, potency etc. to serve 
its best activities.  It is obvious that a little change in the 
formulation or variations in the manufacturing process 
or use of low quality materials can affect the product 
stability and efficacy. It has been reported that due to 
inadequate therapeutic content in antibiotic formulations, 
susceptible organisms gain resistant tremendously 
and many pathogenic organisms have already shown 
resistance to a number of antimicrobial drugs5. Therefore, 
quality and efficacy assessment and maintenance of proper 
dosage schedule of the antimicrobial agents are strongly 
emphasized to ensure their efficacy and safety which can 
be ensured by analyzing the products during and after 
manufacturing and at various intervals during the shelf 
life of the product. Effective process validation contributes 
significantly to assuring drug quality. The basic principle of 
quality assurance is that a drug should be produced that is 
fit for its intended use and does not expose the consumers 
to risks6.
Although several methods have been reported previously 
in the literature for determination of sparfloxacin in 
the pharmaceutical formulations7-12, among them many 
articles have described the use of buffers to develop 
reversed-phase high pressure liquid chromatographic 
(RP-HPLC) method. The use of buffer as a mobile phase 
in HPLC has many limitations as it requires filtration 
before use, crystallization may occur when the organics 
come in contact with leftover buffers in system which 
may damage the pump and column, and also produce 
corrosion of stainless steel lines. Besides these buffers 
require to prepare everyday because especially phosphate 
buffer is a good medium for bacterial and fungal growth. 
To overcome the limitations of buffers,  the objective of 
this work was to develop a more simple, accurate and 
rapid liquid chromatographic analytical method for the 
assay of sparfloxacin in pharmaceutical formulations and 
to validate the method in accordance with the guidelines 
of FDA (Food and Drug Administration, United States of 
America), USP (United States Pharmacopoeia) and ICH 
(International Conference on Harmonization) with respect 
to accuracy, reproducibility, linearity and specificity 13-15.
We, herein, describe an isocratic HPLC method using 1% 
aqueous solution of acetic acid and acetonitrile (71: 29) with 
UV detection instead of buffer. To the best of our knowledge, 
this is the first report of using non-buffer containing 1% 
aqueous solution of acetic acid with acetonitrile to assay 
sparfloxacin of pharmaceutical preparations.
MATERIALS AND REAGENTS 
Working standard of sparfloxacin (potency 99.93%) was a 
kind gift of Drug International Ltd., Dhaka, Bangladesh. 
For the estimation of sparfloxacin formulated as tablets, 
samples were purchased from different manufacturers and 
from retail pharmacies on random basis and were coded as 
Sample-1, Sample-2 and Sample-3. HPLC grade acetic acid 
and acetonitrile were procured from local sources. 
Apparatus
HPLC system 
High Performance Liquid Chromatographic system 
(Shimadzu-UFLC Prominence), equipped with an auto 
sampler (Model- SIL 20AC HT) and UV-Visible detector 
(Model-SPD 20A) was used for the analysis. The data was 
recorded using LC-solutions software. 
Column 
Analytical reversed phase C-8 column [Luna C-8(2), 5 μ, 
150 x 4.6 mm, Phenomenex, Inc] was used to analyze the 
samples.
Mobile phase
Aqueous solution of 1% acetic acid and acetonitrile were 
prepared and sonicated for 10 minutes and then it was 
filtered through a 0.22 μm millipore filter. HPLC grade 
actonitrile was also filtered and degassed before using.
Chromatographic conditions
All analyses were done at ambient temperature under 
isocratic condition. The mobile phase consisted of 1% 
aqueous solution of acetic acid and acetonitrile in the 
ratio of 71% and 29% (v/v) at a flow rate of 0.7 mL/
min. The injection volume was 20 μL for standard and 
samples. Before analysis, every standard and sample were 
filtered through 0.45 μm filter tips. The column eluate was 
monitored at 290 nm. 
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Preparation of standard solutions
Solutions of the standard drug was prepared by dissolving 
25.02 mg of sparfloxacin powder (equivalent to 25.0 mg 
sparfloxacin) in a 25 mL volumetric flask using 10 mL 
of the mobile phase. Then the volume was made up to 
the mark with the same solvent. The final concentration 
obtained was 1.0 mg/mL. Appropriate volume from this 
solution was further diluted to get standards of varying 
concentrations (25, 30, 35, 40, 45, 50, 60 μg/mL). 
Preparation of test sample
Ten tablets in each of the samples (Sample-1, Sample-2 
and Sample-3) were weighed, made into fine powder 
in a mortar with pestle and average weight was taken. 
Accurately weighed powder equivalent to average weight 
of each tablet (25 mg of sparfloxacin) was taken in a 25 mL 
volumetric flask and 10 mL of mobile phase was added 
and sonicated to mix uniformly. The final volume was 
adjusted with mobile phase to get the concentration of 
1.0 mg/mL. The solution was further diluted 20 times to 
get the concentration of 50 μg/mL, filtered through 0.45 
μm filter tips, and aliquots of 20 μL from this solution 
was injected into the HPLC by using an auto injector. The 
average content of the tablets was determined using the 
calibration curve.  
Method validation 
Specificity
The specificity of the LC method was evaluated to ensure 
that there was no interference from the excipients present 
in the pharmaceutical product. The specificity was 
studied by injecting the excipients, standard solution and 
pharmaceutical preparation of sparfloxacin. 
Accuracy/ Recovery
The accuracy of an analytical method expresses the 
nearness between the expected value and the value found. 
It is expressed by calculating the percent recovery (R%) of 
analyte recovered by assay of  spiked samples. In this case, 
aliquot equivalent to 100 μg/mL of sparfloxacin tablet 
solution was taken in three 10 mL volumetric flasks and 
20 μg/mL, 40 μg/mL and 60 μg/mL standard sparfloxacin 
solutions were added to get the final concentrations as 
60 μg/mL, 70 μg/mL and 80 μg/mL, respectively. These 
three solutions were analyzed in successive analysis (n = 
3) using the proposed method to evaluate the accuracy of 
the method. The data of the experiment were statistically 
analyzed to study the reproducibility and validity of the 
proposed method. 
Precision/ Reproducibility 
Precision of the assay was investigated with respect to 
both repeatability and reproducibility. The precision of 
an analytical method is the degree of agreement among 
individuals test result where the method is applied 
repeatedly to multiple samplings. It was checked by intra- 
and inter-day repeatability of responses after replicate 
injections and expressed as RSD % amongst responses 
using the formula [RSD (%) = (Standard deviation/Mean) x 
100 %]. In the current method development and validation 
protocol, precision was determined by three replicate 
analyses of each of the concentrations of 40 μg/mL, 50 μg/
mL, 60 μg/mL of standard sparfloxacin solutions using the 
proposed method.
Linearity 
Five different concentration levels (25 μg/mL, 30 μg/mL, 
35 μg/mL, 40 μg/mL and 45 μg/mL) were prepared from 
standard solution by diluting with the 1% aqueous acetic 
acid solution. Then 20 μL from each solution was injected 
into the HPLC using auto-sampler and the analyses were 
monitored at 290 nm and repeated four times. The average 
peak areas were plotted against concentrations. The 
linearity of the proposed method was evaluated by using 
calibration curves to calculate coefficient of correlation, 
slope and intercept values.
RESULTS AND DISCUSSION
A reversed phase HPLC method has been developed 
and validated as per ICH, USP and FDA guidelines 
for determination of sparfloxacin in pharmaceutical 
formulations by using the mobile phase comprising 
aqueous solution of 1% acetic acid and acetonitrile in the 
ratio of 71% and 29% (v/v) at ambient temperature at 
flow rate of 0.7 mL/min with UV detection at 290 nm. The 
injection volume was kept at 20 μL for standard and all 
samples. The retention time of sparfloxacin was obtained 
at 3.1 ± 0.1 min (Figure 1).
The specificity of the method was monitored by analyzing 
the placebo (containing all the ingredients of the 
formulation except the analyte), standard solution and 
market preparation containing sparfloxacin. No peak was 
detected close to the retention time of sparfloxacin hence 
proving the high degree of specificity of the method.
The accuracy was evaluated at three different 
concentrations with spikes which were conducted in 
successive analysis (n = 4) using the proposed method and 
the value was expressed as percentage of recovery between 
the mean concentrations found and added concentration 
for sparfloxacin. The average percentage of recovery 
was found to be 97.65%, 97.41% and 98.11% for 60 μg/
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mL, 70 μg/mL and 80 μg/mL, respectively (Table 1).  All 
experimental results were in the range of the acceptability 
for precision and accuracy15, which indicated that the 
developed method is sensitive enough and accurate for 
determination of sparfloxacin. 
The precision of the method was evaluated by repeatability 
of sample application and measurement of peak area using 
three replicates of each of the 40 μg/mL, 50 μg/mL, and 
60 μg/mL standards, where the mean concentrations 
were found as 40.49 μg/mL, 49.93 μg/mL and 59.15 μg/
mL with associated %RSDs of 0.32%, 1.66%, and 0.08%, 
respectively. The %RSD values for intra- and inter-day 
assays of sparfloxacin performed in the same laboratory 
did not exceed more than 1.3% (Table 2).
When peak area (y) was plotted against concentration 
levels of 25 μg/mL, 30 μg/mL, 35 μg/mL, 40 μg/mL and 
45 μg/mL, a good correlation coefficient was obtained. For 
the equation of calibration curve, correlation coefficient (r2) 
Figure 1.  HPLC chromatogram of sparfloxacin standard
Table 1. Accuracy of the developed method
Standard

















was obtained as 0.998 which was within the accepted range 
of guidelines and showed good linear relationship of the 
newly developed method with the slope (m) and intercept 
(c) of the calibration curve as 106705.52 and -153223, 
respectively (Table 3, Figure 2). 
By employing this method, the content of sparfloxacin 
was determined in marketed tablets. The sparfloxacin 
formulations available in Bangladesh were purchased 
from different manufacturers on random basis from 
retail pharmacies and coded as Sample-1, Sample-2, and 
Sample-3, and the content of drug was found as 100.07%, 
101.52% and 98.12%, respectively (Table 4), which were 
also in the acceptable range13-16.  
CONCLUSION 
The activity of a drug depends on some absolute 
requirements such as quality, potency etc.  It is obvious 
that a little change in the formulation or variations in the 
14 Ars Pharm. 2012; 53(1): 11-16.
Sultan Z, Zia-Ul-Huda G, Hossain A, Mazid A, Rashid A.





Mean (n = 3) ± SD % Recovery RSD %
Recovered






















Table 3. Linearity of the method
Table 4. Determination of drug content in the sparfloxacin tablets 
Concentration 
(μg/mL)
Mean Area (y) 














Formulation code Amount of sparfloxacin label claimed per tablet (mg)
Amount of sparfloxacin 
found by new method (mg)














Figure 2. Linearity of curve for standard sparfloxacin
manufacturing process or use of low quality materials 
including API (Active Pharmaceutical Ingredients) and 
fake or expired drugs can affect the efficacy of the drug 
as well as may produce harmful effect to the patient to a 
high risk level. Therefore, quality and efficacy assessment 
and maintenance of proper dose schedule are strongly 
emphasized to ensure the effectiveness of the drug. 
To ensure the requisite quality, drug manufacturers 
are required to test their products during and after 
manufacturing processes and at various intervals during 
the shelf life of the product. Hence, we planned to study 
and determine the potency and efficacy of most commonly 
used antimicrobial preparations like sparfloxacin, a 
broad spectrum antibiotic which is widely prescribed in 
Bangladesh.
To attain this objective, a rapid and sensitive reversed 
phase high performance liquid chromatographic method 
was developed and validated according to the guidelines 
of FDA, ICH and USP with respect to accuracy, precision, 
specificity and linearity. The developed method was found 
to be simpler, accurate, reproducible, efficient and less time 
consuming, and was applied successfully for the study of 
sparfloxacin formulations. 
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